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We have raised an antibody specifically recognizing endogenous mouse SRYprotein and used it to investigate the molecular and cellular mode
of action of SRY in testis determination. We find that expression of SRY protein closely mirrors the expression of Sry mRNA in mouse genital
ridges and is detectable for 6 to 8 h after the mRNA ceases to be detectable. The subset of somatic cells that expresses SRY begins to express
SOX9 almost immediately. Since these SOX9-positive cells go on to develop as Sertoli cells, it appears that SRY expression marks the pre-Sertoli
cell lineage and leads to up-regulation of Sox9 expression cell-autonomously. However, a small proportion of SOX9-positive cells did not appear
to express SRY, possibly reflecting the additional involvement of paracrine signaling in activating Sox9 transcription in these cells. We confirmed
by ex vivo cell mixing experiments that SRY is able to engage receptor-mediated signaling to up-regulate Sox9 expression. Finally, we showed by
employing specific inhibitors that the causative signaling molecule is prostaglandin D2 (PGD2) and that PGD2 can induce Sox9 transcription in
cultured XX gonads. Our data indicate a mechanism whereby Sry uses both a cell-autonomous mechanism and a PGD2-mediated signaling
mechanism to stimulate expression of Sox9 and induce the differentiation of Sertoli cells in vivo.
D 2005 Elsevier Inc. All rights reserved.Keywords: SRY; Sox9; Gonad development; Sex determination; Testis differentiation; Prostaglandin; Sertoli cellIntroduction
Sry, the gene that encodes the Y-chromosomal testis-
determining factor, plays a singularly important role in the
developmental, reproductive and social biology of mammals.
In all but a few exceptional cases, expression of Sry in the XY
gonadal primordia, the genital ridges, triggers a complex
cascade of events that begins with the development of testes
and ultimately results in the myriad features that distinguish
male from female (Koopman et al., 1991). Despite the pivotal
role of Sry, very little has been learned about its regulation, the0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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New Zealand.molecular mode of action of the transcription factor it encodes,
and the direct cellular consequences of its action.
Early development of the XY gonad is characterized by
increased cell proliferation (Schmahl et al., 2000), induction of
cell migration from the adjacent mesonephroi into the gonads
(Capel et al., 1999; Martineau et al., 1997), differentiation of
male-specific cell lineages such as Sertoli cells, peritubular
myoid cells, and steroidogenic Leydig cells, morphogenetic
events such as cord formation and patterning of a characteristic
vasculature (Brennan et al., 2002), and induction of mitotic
arrest in the testicular germ cells (McLaren and Southee, 1997).
Although these are male-specific events that, by definition,
occur downstream of Sry, it is not known which, if any, are
direct consequences of the action of the SRY transcription
factor.
Sry gene expression has been studied in detail in an effort to
gain insights into the molecular and cellular roles of the gene.
Nuclease protection, RT-PCR and in situ hybridization studies87 (2005) 111 – 124
www.e
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around 10.5 days post coitum (dpc) first in the center and then
in the rostral pole of XY genital ridges, reaches maximum
levels at 11.5 dpc throughout the whole length of the gonad,
regresses to the caudal pole, and ends around 12.5 dpc
(Bullejos and Koopman, 2001; Hacker et al., 1995; Jeske et
al., 1995, 1996; Koopman et al., 1990). Because Sry encodes a
putative transcription factor that contains an HMG DNA-
binding domain, it is thought that SRY must act within a brief
window of time to activate (Dubin and Ostrer, 1994) or repress
(Desclozeaux et al., 1998; McElreavey et al., 1993) target
genes, but these remain to be identified.
One gene that acts downstream of Sry and is a strong
candidate for an SRY target is Sox9. Like Sry, Sox9 has been
shown to be necessary and sufficient for male development:
gain-of-function in humans and mice results in XX sex reversal
(Bishop et al., 2000; Huang et al., 1999; Vidal et al., 2001),
while loss-of-function leads to skeletal defects and XY sex
reversal (Foster et al., 1994; Wagner et al., 1994). Sox9
expression in male genital ridges is first detected shortly after
the onset of Sry expression and follows a similar dynamic wave
(Kent et al., 1996; Morais da Silva et al., 1996; Schepers et al.,
2003), but, unlike Sry, Sox9 continues to be expressed in the
testes throughout fetal development. While Sry may directly or
indirectly activate Sox9, it is clearly not required for continued
Sox9 expression, which may be auto-regulatory. Recent studies
have indicated that Sry expression persists in XY gonads
deficient in Sox9 (Chaboissier et al., 2004; Sekido et al., 2004),
suggesting that SOX9 protein may be responsible for the rapid
extinction of Sry expression around 12.5 dpc. Despite these
possibilities, a regulatory relationship between the two genes
has been impossible to prove.
It has been postulated that Sry serves to initiate pre-Sertoli
cell differentiation and that these cells act as signaling centers
to direct subsequent differentiative events. In support of this
hypothesis, pre-Sertoli cells are the first to differentiate in the
XY gonad. Early XX6XY chimera studies showed that most,
but not all, Sertoli cells are XY, whereas other lineages are
composed of XX and XY cells (Burgoyne et al., 1988; Palmer
and Burgoyne, 1991). These results suggested that, in addition
to the main cell-autonomous action of the testis-determining
gene in inducing pre-Sertoli cell differentiation, a paracrine
signaling mechanism might exist that is able to recruit cells that
lack Sry expression to a Sertoli cell fate. However, the
possibility of a paracrine signaling-mediated mechanism of
inducing Sertoli cell differentiation has received little attention
compared to the focus on cell-autonomous transcriptional
pathways. The existence of a signaling factor has not been
substantiated, and the identity of any signaling factor has not
been elucidated.
In the present study, we use a novel antibody that avidly and
specifically recognizes native mouse SRY protein to study in
detail the expression of SRYand its relationship with Sox9. Use
of this antibody, combined with in vitro and ex vivo analyses,
indicates that SRY causes cell-autonomous up-regulation of
Sox9 expression. In addition, our studies reveal that the
paracrine signaling component involves prostaglandin D2,which is necessary and sufficient to recruit SRY-negative cells
to up-regulate Sox9 expression and therefore become pre-
Sertoli cells.
Results
An antibody specific to SRY
A fuller understanding of the molecular and cellular roles of
SRY during male sex determination and early differentiation of
the XY gonad has been hampered by the unavailability of an
antibody with which to study the expression and properties of
SRY protein. In the present study, we raised antibodies against
mouse SRY by immunizing rabbits with a bacterially expressed
purified protein comprised of glutathione-S-transferase (GST)
fused to the 314-amino-acid portion of the SRY polypeptide C-
terminal to the HMG domain (Fig. 1A). Western blot analysis
showed that the affinity-purified antibody detects SRY in
protein extracts from Sry-transfected COS7 cells and from XY
mouse genital ridges isolated at 11.5 dpc, but not in extracts
from untransfected, Sox9- or Sox8-transfected cells, 11.5 dpc
XX genital ridges, or 13.5 dpc gonads of either sex (data not
shown).
Immunofluorescence staining assays of COS7 cells using
this antibody showed a clear signal in cells transfected with an
HA-tagged-SRY expression plasmid (HA-Sry), but not in
mock-transfected (data not shown) or HA-Sox9- or HA-Sox8-
transfected cells (Fig. 1B). Using an antibody specific for the
HA tag confirmed that all proteins were expressed in these
experiments (Fig. 1B).
In sections of 11.5 dpc mouse embryos, the stage of
maximal Sry mRNA expression (Bullejos and Koopman, 2001;
Hacker et al., 1995; Jeske et al., 1995; Koopman et al., 1991),
immunofluorescence staining revealed a signal in cells
scattered throughout XY genital ridges but not in XX samples
or any other tissues (Fig. 1C). However, we sometimes
observed staining, probably due to the secondary antibodies,
in blood cells in both sexes (e.g. Fig. 2—13 ts, Fig. 3A).
Double staining with an antibody recognizing platelet endo-
thelial cell adhesion molecule-1 (PECAM-1), which is
expressed on the cell surface of endothelial and germ cells,
showed that SRY is expressed only in somatic cells of the
genital ridge (Figs. 1C, D). As expected, staining was observed
in cell nuclei, but not in the cytoplasm or nucleoli. Interest-
ingly, high-power imaging revealed that endogenous SRY is
expressed in a punctate manner in the nuclei (Fig. 1E).
Together, this pattern of reactivity on Western blots,
transfected cells, and embryo sections shows that the novel
antibody described in this study is specific for SRY protein.
Expression of SRY during XY gonadal development
Generation of an antibody, able to detect native SRY in situ,
allowed us to investigate the molecular and cellular functions
of this critical protein. We first examined in detail the spatial
and temporal expression pattern of SRY in XY genital ridges
by immunofluorescence analysis of sections of mouse embryos
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ts (shortly after 12.5 dpc). At 11 ts, a small number of cells in
the center of the genital ridge were positive for SRY protein(Fig. 2A, lower row, arrowhead). The number of SRY-positive
cells subsequently increased, and the expression domain
expanded from the center to the poles, so that SRY-positive
somatic cells were detectable along the entire length of the
gonads by 18 ts. The domain of SRY expression receded in a
rostral-to-caudal wave, leaving a population of SRY-positive
cells at the caudal pole by 30 ts and disappearing completely by
34 ts (Fig. 2A).
This wave-like progression of SRY protein expression
closely mirrors the dynamics of Sry mRNA expression (Fig.
2A, upper row; Bullejos and Koopman, 2001). The ability to
detect SRYprotein slightly before the Sry mRNA expression at
11 ts presumably is due to differences in sensitivity of the
respective detection methods.
Cell-autonomous up-regulation of SOX9 in SRY-positive
pre-Sertoli cells
We next compared the expression of SRY with that of its
potential target gene Sox9. Double-label immunofluorescence
using antibodies specific for SRY (green) and SOX9 (red)
showed that, at the 14 ts stage, SOX9 protein becomes
detectable in the center of the genital ridge in cells that are
also positive for SRY (Fig. 3A, yellow cells). At 16 ts, most of
the cells expressing SRY also expressed SOX9 and vice versa.
From 18 ts, the number of cells expressing only SOX9 (red
cells) increased relative to the number of double-positive cells,
indicating that Sry expression starts to be down-regulated in
some cells at this stage. Interestingly, at all stages examined,
cells that expressed only SRY could be detected, suggesting
that not all SRY-positive cells come to express SOX9. High
power images revealed a variety of different expression levels
of SRYand SOX9 in the somatic cells of XY gonads (Fig. 3B).
These co-expression profiles suggest that SRY expression
rapidly leads to SOX9 expression in the same cell lineage.
These SOX9-expressing cells go on to become Sertoli cells that
line the testis cords (Fig. 3C) and express the gene encoding
anti-Mu¨llerian hormone (Amh). Since it has been established
that SOX9 expression marks Sertoli cells at all stages of
development (Kent et al., 1996; Morais da Silva et al., 1996;
Hanley et al., 2000; de Santa Barbara et al., 2000; Sekido et al.,Fig. 1. Characterization of the anti-SRY antibody. (A) Schematic representation
of the fusion protein used to immunize rabbits. The 5V-part (nucleotides 1–
243), including the sequence encoding the HMG domain, of mouse Sry was
replaced by a fragment encoding glutathione-S-transferase (GST). This
construct was expressed in bacteria, and the resulting protein was purified
for immunization. Numbers refer to amino acids. (B) Immunofluorescence
staining with the anti-SRY antibody (left column) or an anti-HA antibody (right
column) of COS7 cells transfected with an expression plasmid for HA-SRY
(upper row), HA-SOX8 (middle row), and HA-SOX9 (bottom row),
respectively. The anti-SRY antibody is specific for SRY and does not cross-
react with either SOX8 or SOX9. Staining with the anti-HA antibody confirmed
that all proteins were expressed. Scale bar, 100 Am. (C, D) Double
immunostaining for SRY (green) and PECAM-1 (red) on sagittal sections of
11.5 dpc XY (left) and XX (right) embryos. PECAM-1 is a cell surface marker
for germ cells and vascular endothelium. SRY is found exclusively in nuclei of
somatic cells of XY genital ridges. Scale bars, 100 Am (C) and 25 Am (D),
respectively. (E) High power images of an immunostained somatic XY gonadal
cell expressing SRY showing a punctate nuclear localization. Scale bar, 10 Am.
Fig. 2. Spatial and temporal expression pattern of SRY mRNA and protein. Section in situ hybridization for Sry (upper row) and double immunofluorescence of SRY
(green) and PECAM-1 (red) (lower row) on XY, tail-somite-staged embryos from 11 ts to 34 ts. Both Sry mRNA and protein are expressed in a dynamic wave and
during a restricted time window in the male genital ridge. The discrepancy of the onset of mRNA expression (13 ts) to protein expression (11 ts, arrowhead) is
probably due to differences in sensitivity of the detection methods employed. Scale bar, 100 Am.
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SRY expression marks the pre-Sertoli cells of the XY genital
ridges.
Non-cell-autonomous recruitment of SOX9-positive cells
When we examined closely the pattern of SRY and SOX9
immunofluorescence staining in the XY genital ridge, we
occasionally saw a small number of SOX9 single-positive cells
even as early as 14 ts stage, the time point at which Sox9
expression starts to become up-regulated (Figs. 3A arrowhead
and D). Although it is possible that these cells may have
experienced an early pulse of Sry expression and that SRY
protein is no longer present in these cells by 14 ts, we
considered it possible that these cells might never have
expressed Sry, instead coming to express Sox9 as a result of
signaling from SRY/SOX9-positive cells.
To test directly for possible involvement of paracrine
signaling mechanisms, we used a cell mixing approach, in
which we combined dissociated 12.25 dpc XY genital ridge
cells from a wild type mouse strain with dissociated 12.25 dpc
XX genital ridge cells from a transgenic strain constitutively
expressing EGFP (Hadjantonakis et al., 1998) and vice versa.
The mixed cell populations were aggregated by centrifugation,
cultured for 36 h, and analyzed by FACS for the distribution of
SOX9 immunoreactivity and EGFP fluorescence to distinguish
between XX and XY cells (Fig. 4A). These analyses showed
that some 12% of cells derived from XY genital complexes at
this stage of development express SOX9—i.e., are pre-Sertoli
cells (Figs. 4C and D). Although most XX cells did not express
SOX9, a small proportion of them (approximately 3%,
representing approximately 25% of the XX supporting cell
lineage) became SOX9-positive as a result of exposure to XY
genital ridge cells (Figs. 4C and D). This pattern of staining wasnot observed when XX–EGFP cells were mixed with XX–wild
type genital ridge cells (Fig. 4B), showing that the induction of
SOX9 expression in XX cells is not due to dissociation and re-
aggregation of the cells. These experiments confirm that XY
cells are able to recruit XX cells to express SOX9 through either
a juxtacrine or paracrine signaling mechanism.
We always observed a difference in the percentage of XX
SOX9-positive cells between the experiments in which the XX
cells were derived from EGFP-transgenic embryos (Fig. 4C) to
that from wild type embryos (Fig. 4D). This difference is due to
the loss of EGFP protein from the cytoplasm of the
permeabilized cells during the washes between the antibody
staining and therefore a shift of EGFP-positive cells to the
EGFP-negative cell population.
To test whether paracrine signaling is critical for the
recruitment phenomenon, we repeated the cell mixing experi-
ments in the presence of the drug suramin. Suramin, a
polysulfonated naphtylurea, has been shown to inhibit numer-
ous signaling molecules, including growth factors and inter-
leukins (Voogd et al., 1993), G-proteins (Freissmuth et al.,
1996), and enzymes such as reverse transcriptase (De Clercq,
1987). Culture of the XX–XY gonad cell aggregates in the
presence of 0.3 mM suramin completely abrogated the
recruitment of XX cells to the SOX9-positive population
(Fig. 4E), confirming that receptor-mediated signaling is
required for this recruitment. Furthermore, the proportion of
XY SOX9-positive cells decreased from 12% to around 10%,
indicating that paracrine signaling is also active in normal XY
gonad development.
Identification of the paracrine signal as prostaglandin D2
Several extracellular signaling molecules have been shown
to play a role in testis development (reviewed by Brennan and
Fig. 3. Relationship between SRY- and SOX9-expressing cells in the developing genital ridges. (A) Double immunofluorescence of SRY (green) and SOX9 (red) on
sagittal sections of XY embryos from 14 ts to 25 ts. SRY-positive cells almost immediately start to express SOX9 also (yellow cells). However, infrequently, a few
cells seem to express SOX9 without having expressed SRY before (14 ts, arrowhead). Upon down-regulation of SRY (from 18 ts stage), the number of SOX9-single
positive cells increases. Scale bar, 100 Am. (B) High power image of double immunostaining for SRY (green) and SOX9 (red) of a sagittal section of an XY embryo
shows a diversity of SRY and SOX9 expression levels at 22 ts stage. Scale bar, 25 Am. (C) Double immunofluorescence of PECAM-1 (red) with SRY (green,
left) or SOX9 (green, right) on serial sagittal sections of XY embryos. At 30 ts, only a small domain of SRY-positive cells can be detected at the caudal pole,
whereas SOX9-expressing cells have differentiated into Sertoli cells lining the testicular cords. Scale bar, 100 Am. (D) Enlargement of the region marked with a
rectangular in (A-14 ts) shows the SOX9-single positive cells (red).
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Colvin et al., 2001; Schmahl et al., 2004), prostaglandin D2
(PGD2; Adams and McLaren, 2002, Malki et al., 2005), Desert
hedgehog (DHH; Yao and Capel, 2002), and platelet-derived
growth factor alpha (PDGFa; Brennan et al., 2003). Mice
lacking either DHH or PDGFa show defects in testis formation
and Leydig cell differentiation. However, differentiation of
Sertoli cells is not impaired, suggesting that these factors might
not be involved in the observed recruitment of cells to the
Sertoli cell fate. In contrast, FGF9-deficient mice fail to express
the Sertoli cell markers Sox9 and Amh, resulting in male to
female sex reversal (Colvin et al., 2001). PGD2 has been shown
to partially masculinize XX gonads in culture, probably byforcing female cells to become Sertoli cells (Adams and
McLaren, 2002). These data suggest that either FGF9 or PGD2,
or both, may act as a paracrine factor to induce Sertoli cell
differentiation in vivo.
To test this hypothesis, we first examined by real-time RT-
PCR the expression of Fgf9 and prostaglandin D synthetase
(Pgds), the enzyme responsible for the production of PGD2,
compared to Sry and Sox9 in XY and XX urogenital ridges at
stages between 12 and 28 ts. If PGD2 and/or FGF9 function as
the paracrine signaling molecule, we would expect them to be
up-regulated in a male-specific manner shortly after Sry and
Sox9. The expression profiles of Sry and Sox9 confirmed the
results obtained previously by RT-PCR, in situ hybridization
D. Wilhelm et al. / Developmental Biology 287 (2005) 111–124116and immunofluorescence (Figs. 2 and 3, and Bullejos and
Koopman, 2001; Hacker et al., 1995; Jeske et al., 1995, 1996;
Koopman et al., 1990). Sry mRNA levels in XY genital ridgeswere already increasing at 12 ts, reaching a peak around 17 ts
and declining to undetectable levels by 27 ts (Fig. 5A). Sox9
expression was up-regulated immediately after Sry, reaching a
Fig. 5. Expression profiling of Sry, Sox9, Pgds, and Fgf9 during early gonad development. Levels of (A) Sry, (B) Sox9, (C) Pgds, and (D) Fgf9 were measured by
real-time RT-PCR of XY and XX urogenital ridges (gonad + mesonephros) collected from embryos between 12 ts and 29 ts. Sry mRNA levels were already
increasing at 12 ts, reaching a peak at around 17 ts before declining to undetectable levels at 27 ts. Sox9, Pgds, and Fgf9 showed early male-specific up-regulation
progressing into a plateau. Direct comparison of the expression profiles (E) revealed a cascade of gene expression in the order of Sry, Sox9, Pgds. y axis (A–D):
RFE (18S)=relative fold expression in comparison to 18S. y axis (E): % maximum expression = maximal level of expression set as 100%.
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Pgds and Fgf9 showed similar expression profiles to Sox9, with
early male-specific up-regulation progressing to a plateau (Figs.
5C and D). Direct comparison of the expression profiles during
male gonadogenesis (Fig. 5E) revealed a cascade of gene
expression in the order Sry, Sox9, and Pgds, supporting a model
in which PGD2 acts as secreted factor inducing Sertoli cell
differentiation (see below).
Our cell mixing experiments (Fig. 4) revealed that a paracrine
factor has the ability to induce Sox9 expression in XX gonadalFig. 4. XY gonadal cells are able to recruit XX cells to express SOX9. (A) Schem
different combinations) re-aggregated 12.25 dpc gonadal cells were cultured for 3
analysis. Co-culture of XX–wild type with XX–GFP cells did not lead to up-regula
GFP (C), or vice versa (D), led to a significant number (P < 0.001) of XX SOX9-p
express SOX9 was completely blocked by 0.3 mM suramin (E, upper right) or 1 AM
SU5402, an inhibitor of FGF signaling, showed only a minor reduction in XX SOX9-
all XX cells and all XY cells, respectively.cells. To determine whether FGF9 or PGD2might be responsible
for this recruitment, we next treated 11.5 dpc XX gonadal
explants with exogenous FGF9 or PGD2 and tested for Sox9
expression by in situ hybridization. Fig. 6A shows that treatment
of XX gonads with FGF9 resulted in an increase in proliferation,
as described previously (Schmahl et al., 2004), but not in Sox9
expression. In contrast, treatment with PGD2 led to a clear up-
regulation of Sox9 transcription (Fig. 6A).
To confirm this effect, we repeated the treatment of gonad
explant cultures with PGD2 and measured the mRNA levels ofatic representation of the experimental procedure. (B–G) Dissociated and (in
6 h, immunostained for SOX9 expression, and subjected to flow cytometric
tion of SOX9 in XX cells (B), whereas co-culture of XY–wild type with XX–
ositive cells (upper right in C, upper left in D). This recruitment of XX cells to
BWA868C, an inhibitor of PGD2 signaling (F, upper right). In contrast, 30 AM
positive cell numbers (G, upper right). Numbers shown are percentage values of
Fig. 6. Exogenous PGD2 activates Sox9 and Amh transcription in XX gonadal explants. (A) Whole-mount in situ hybridization for the Sertoli cell marker Sox9 on
XX control gonads, XX gonads treated with 50 ng/ml FGF9 or 500 ng/ml PGD2, and XY control gonads. Treatment of XX gonad explants with FGF9 caused
increased proliferation resulting in visibly larger gonads, whereas exogenous PGD2 induced the expression of Sox9 comparable to XY gonads of the same stage. All
samples were collected at 11.5 dpc and cultured for 24 h. (B) Real-time analysis of Sox9 and Amh expression of untreated XY gonad explants and XX gonad
explants treated with 500 ng/ml PGD2. Fold change is shown relative to vehicle-treated XX control gonad explants. PGD2 up-regulated both Sox9 and Amh in XX
gonads to levels higher than detected in male control gonads.
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cultured in the presence of 500 ng/ml PGD2 showed a massive
up-regulation of Sox9 and Amh mRNA relative to vehicle-
treated controls (Fig. 6B, gray bars). The degree of up-
regulation observed was higher than that normally seen in XY
gonads at the same stage (Fig. 6B, black bars). These results
indicate that the masculinization effect of PGD2 reported by
Adams and McLaren (2002) is mediated by stimulating
expression of Sox9.
Finally, to test whether PGD2 is the only factor necessary for
recruitment of SOX9-positive cells, we carried out XX–XY
genital ridge cell aggregation experiments in the presence of
inhibitors specific for different signaling pathways. BW
A868C, a compound that specifically targets the classical
PGD2 receptor DP (Boie et al., 1995; Giles et al., 1989; Hirata
et al., 1994; Kiriyama et al., 1997), completely abolished the
recruitment of XX cells to the SOX9-positive phenotype (Fig.4F), whereas SU5402, an FGF receptor 1 antagonist, showed
only a negligible effect (Fig. 4G). Thus, we could demonstrate
that PGD2 is both necessary and sufficient for this paracrine
recruitment mechanism in the XY genital ridge.
Discussion
In this study, we have described the expression character-
istics of native SRYprotein during XY gonadal development in
vivo, without reliance on transgenic reporter strains, cell culture
models, and other such systems, using a novel polyclonal
antibody raised against a partial SRY protein. We have
described the molecular mechanism underpinning earlier
observations suggesting a non-cell-autonomous component to
the action of the testis-determining gene Sry (Burgoyne et al.,
1988; Palmer and Burgoyne, 1991) and others suggesting PGD2
as a possible inducer of testis development (Adams and
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Sox9 transcription and that specific blockade of its receptor
completely abolishes the recruitment under the experimental
conditions used. These observations suggest a model that
describes the early steps of male sex determination in mammals.
Direct visualization of endogenous SRY expression during XY
gonad development
Almost 15 years have passed since the identification of Sry
as the gene encoding the testis-determining factor. Early hopes
that the discovery of Sry might lead to rapid unfolding of the
molecular pathway leading to testis determination and male
sexual development have not been realized, partly due to the
lack of an antibody avidly and specifically recognizing the
native mouse SRYprotein. An antibody recognizing a synthetic
16-amino-acid peptide corresponding to a region N-terminal to
the HMG domain of human SRY (Poulat et al., 1995) has
proven to be of little value as this region is not present in
mouse SRY (reviewed by Koopman, 1999). Alternative
approaches have used SRY reporter fusion transgenes
(Albrecht and Eicher, 2001) or epitope-tagged Sry transgenes
(Sekido et al., 2004) to investigate the expression of SRY
protein indirectly, but, in these studies, the temporal and spatial
fidelity of transgene expression cannot be guaranteed because
the sequences required for accurate regulation of Sry expres-
sion have not been delineated, and the effect of reporter tagging
on post-transcriptional processing (mRNA or protein stability,
translational efficiency, etc.) cannot be gauged. Using a novel
antibody developed in the present study, we were able to
address several important questions relating to the molecular
and cellular mode of action of this pivotal transcription factor
in its native form.
RNA-based methods such as reverse transcriptase-poly-
merase chain reaction (Jeske et al., 1995, 1996; Koopman et
al., 1990), ribonuclease protection (Hacker et al., 1995), and
in situ hybridization (Bullejos and Koopman, 2001) showed
that Sry mRNA is expressed in the male urogenital ridge in a
dynamic wave from 11 ts to 27 ts. We showed that this wave
is closely followed by the expression of SRY protein, starting
at 11 ts and ending with the last SRY-positive cells detectable
at 30 ts, ceasing entirely by 34 ts, suggesting that SRY protein
is immediately and efficiently translated. Our findings
contradict those recently reported by Taketo et al. (2005)
who, using a novel SRY antibody, detected the onset of SRY
protein expression along the entire length of the gonad
simultaneously. The reasons for this discrepancy are not clear;
in our analysis, entire embryos were serial-sectioned and
stained, so as not to overlook any domains of expression. Our
study of endogenous mouse SRY confirmed the findings of
Sekido et al. (2004), who used a tagged Sry transgene, that
the protein is not expressed in germ cells or cells of the
coelomic epithelium and that it is localized in the nuclei and
not detectable in the cytoplasm. It is known that Sertoli cells
are derived from a population of cells that migrates into the
genital ridges from the coelomic epithelium (Karl and Capel,
1998). Our data confirm the suggestion, based on studies ofmRNA (Bullejos and Koopman, 2001) and transgene
expression (Sekido et al., 2004), that SRY expression is
initiated in this precursor cell population only after immigra-
tion has occurred and therefore does not initiate the
immigration.
It has been believed for some time that the Y-encoded testis-
determining factor acts in the supporting cell precursor lineage
of the genital ridges, inducing these cells to develop as pre-
Sertoli cells which produce factors that influence the male
development of other bipotential cell lineage precursors in the
genital ridges (for review: Brennan and Capel, 2004). Albrecht
and Eicher (2001) showed, using transgenic mice expressing
enhanced green fluorescent protein (EGFP) under the control
of Sry cis-regulatory sequences, that the EGFP-expressing cells
could give rise to Sertoli cells in XY mice or granulosa cells in
XX mice. Sekido et al. (2004) also found that cells in
transgenic mice expressing an SRY-hPLAP fusion protein
differentiated as Sertoli cells. Our present observations
confirm, using studies of native SRY expression in vivo, that
SRY labels the cell population in XY genital ridges that co-
expresses Sox9 and develops as Sertoli cells.
Mouse SRY protein was localized in a punctate pattern
within the nuclei, as has been reported for human SRY and its
interacting protein SIP-1 (Ohe et al., 2002; Poulat et al., 1997;
Poulat et al., 1995). This might indicate a role of SRY in
mRNA splicing, as suggested by Ohe et al. (2002). Further
work will be required to assess whether endogenous mouse
SRY is able to bind to RNA and is co-localized with splicing
factors in vivo.
Cell-autonomous activation of Sox9 following SRY expression
in vivo
Sox9 is thought to be a target gene of Sry, based on their
temporal and spatial expression patterns during testis devel-
opment. The exact nature of the regulatory relationship
between SRY and Sox9 has been a subject of considerable
debate. Our immunofluorescence and real-time PCR analyses
show that Sox9 activation closely follows Sry in the pathway.
However, we found SRY-positive cells that did not express
SOX9 even at late stages when SRY expression declines.
Possible explanations could be either that these cells have not
yet switched on SOX9 expression and/or that SRY was not
expressed at high enough levels to induce Sox9 expression.
Indeed, it has been suggested that Sry has to reach a certain
threshold to activate Sox9 expression and initiate testis
differentiation (Lee and Taketo, 1994; Sekido et al., 2004).
Further support for this theory comes from cell transfection
experiments, where very low as well as very high amounts of
Sry expression plasmid did not cause the up-regulation of
endogenous Sox9 expression (data not shown), suggesting
that only a certain range of Sry expression is capable of
activating Sox9 expression.
The brief period of SRY protein expression supports the
model, based on mRNA expression studies, that SRY must act
within a limited developmental window in order to affect male
sex determination (Bullejos and Koopman, 2005). Our present
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which to activate Sox9 transcription in individual pre-Sertoli
cells in mice. After Sox9 is activated, its transcription is
sustained by a mechanism that is independent of Sry, perhaps
by auto-regulation. Accumulating evidence suggests that
expression of Sox9 is responsible for down-regulation of Sry
transcription (Chaboissier et al., 2004). This model is
supported by our studies of SRY and SOX9 protein expression
at late stages (30 ts), where SRY could only be detected in the
posterior pole, a region that has not yet begun to express SOX9
(Fig. 3C).
A non-cell-autonomous pathway downstream of SRY in XY
gonad development
Early studies of Burgoyne et al. (1988) showed that, in
XX6XY chimeras, Sertoli cells are exclusively XY, whereas
other lineages are composed of XX and XY cells, indicating
cell-autonomous action of the testis-determining gene in
inducing pre-Sertoli cell differentiation. However, re-analysis
of earlier stage XX6XY chimeras showed that not all Sertoli
cells are XY, suggesting the existence of a paracrine signaling
loop that is able to recruit cells lacking Sry expression to a
Sertoli cell fate (Palmer and Burgoyne, 1991). This concept
has proven difficult to incorporate into molecular models of
Sry action. We found that some SOX9-positive, SRY-negative
cells arise in the gonad at a very early stage. One possible
explanation is that these cells might have undergone a short
pulse of Sry expression early and no longer retain SRY protein
by the 14 ts stage. Alternatively, these cells might never have
expressed SRY, instead were being recruited to become
SOX9-positive via paracrine signaling from their SRY/
SOX9-positive neighbors. Indeed, both mechanisms may
occur.
Our cell mixing experiments provide supporting evidence
that a paracrine recruitment mechanism exists, at least under
experimental conditions, and revealed the molecular nature
of this recruitment. For practical reasons these experiments
were conducted using gonads from 12.25 dpc embryos, the
earliest stage at which it was possible to sex the gonads
morphologically. PGD2 signaling most likely occurs in vivo
at 11.5 dpc to recruit Sertoli cells, and so the underlying
assumption is that signaling events occurring in experimen-
tal samples at 12.25 dpc reflect events occurring in vivo at
11.5 dpc.
Identification of PGD2 as the signaling molecule involved in
Sertoli cell recruitment
Recently, a possible role for PGD2 as a paracrine inducer of
Sertoli cell differentiation has been proposed, based on
observations that exposure to exogenous PGD2 could cause
up-regulation of Amh expression in female embryonic gonads
in culture (Adams and McLaren, 2002), although the relevance
in vivo has not been clear. Our data reveal that this effect is
mediated by up-regulation of Sox9 and imply that PGD2 might
act in vivo during testis development to induce paracrinerecruitment of supporting cells to express Sox9 in the absence
of Sry. It also appears that PGD2 signaling is necessary for this
recruitment since blocking of the DP receptor abrogates the
effect, whereas antagonists of other signaling pathways were
ineffective. The DP inhibitor we used has been shown to be
highly specific, for example, effects on other prostaglandin
receptors were excluded at concentrations up to 1000 times
higher than the DP receptor affinity (Giles et al., 1989;
Kiriyama et al., 1997). To confirm our conclusions genetically
and in vivo would require close observation of XY PGDS- or
DP receptor knockout fetal gonads to check for the absence of
the few cells that we believe are normally recruited to the
Sox9-positive Sertoli cell lineage without expressing SRY, an
approach that presents a formidable challenge and rests on
negative data.
Malki et al. (2005) proposed recently that PGD2 acts as
an autocrine factor inducing SOX9 nuclear translocation and
subsequent Sertoli cell differentiation. However, we cannot
find any evidence of change in subcellular localization of
SOX9 protein during mouse gonad development. Like
Sekido et al. (2004), we were unable to detect SOX9
protein in the cytoplasm in any gonadal cells. The only
cytoplasmic SOX9 we could observe was at low levels at
early stages in mesonephric cells (data not shown). More-
over, at the time when we first see SOX9 in the nuclei of
pre-Sertoli cells (14 ts stage), we cannot yet detect any
prostaglandin D synthetase mRNA (Fig. 5). Together, our
observations suggest that the main function of PGD2 is to
enhance Sox9 transcriptional levels rather than influencing
subcellular localization.
What is the significance of this paracrine recruitment
mechanism during XY gonad development? Mice lacking
PGDS or the DP receptor do not develop an abnormal gonadal
phenotype (Eguchi et al., 1999; Matsuoka et al., 2000),
consistent with our finding that the major mechanism of
Sox9 up-regulation is via cell-autonomous action of SRY. In
cells, where Sox9 is not activated through cell-autonomous
action of SRY, recruitment by neighboring cells to express
Sox9 might serve to maximize the number of supporting cells
that eventually develop as Sertoli cells, effectively acting as an
insurance mechanism to canalize gonadal development towards
testicular development. The fact that such a mechanism exists
may point to a more important role in wild mice than its
observed secondary role in laboratory strains. This mechanism
may also be important in strains bearing a Fweak_ Sry allele,
such as those from Mus musculus domesticus strains that
appear unable to direct complete testis development when
combined with the C57BL/6 genetic background (Eicher et al.,
1982). Consistent with the proposed importance of localized
paracrine recruitment in these situations, resultant ovotestes are
composed of large blocks of ovarian and testicular tissue rather
than interspersed ovarian and testicular cell types (Nagamine et
al., 1999).
In view of the present data and results of previous studies,
we propose the following model for the earliest steps of the
male sex-determining pathway (Fig. 7). SRY can induce Sox9
transcription cell-autonomously via either a direct or indirect
Fig. 7. Model for cell-autonomous and PGD2 signaling mediated up-regulation
of Sox9 in pre-Sertoli cells. Sry induces Sox9 cell-autonomously either via a
direct or indirect regulatory mechanism!. Sox9 represses the transcription of
Sry " and maintains its own expression in an auto-regulatory loop #. In
addition, Sry and/or Sox9 serve to up-regulate Pgds $, which leads to PGD2
synthesis and secretion. PGD2 can act, via its DP receptor, to up-regulate Sox9
expression in a paracrine and possibly also an autocrine manner %. Thus,
supporting cells that fail to reach a threshold of Sry expression [shown as (Sry)]
can be induced to up-regulate Sox9 and differentiate as Sertoli cells.
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2004). SOX9 represses the transcription of Sry, either directly
or indirectly (Chaboissier et al., 2004; Sekido et al., 2004). In
the absence of continued SRY expression, SOX9 most likely
maintains its own expression through positive auto-regula-
tion. In addition to these cell-autonomous mechanisms
operating in pre-Sertoli cells, SRY and/or SOX9 serve to
up-regulate Pgds. Secreted PGD2 can act via its DP receptor
to up-regulate Sox9 transcription in a paracrine and possibly
also an autocrine manner. This paracrine loop may be
assisted by the germ cells, which also express Pgds (Adams
and McLaren, 2002). It will be of interest to identify other
targets of SRY and SOX9 in order to further illuminate this
pathway.
Methods
Animals and cell lines
Embryos were collected from timed matings, with noon of the day on which
the mating plug was observed designated 0.5 days post coitum (dpc). For more
accurate staging, the tail somite (ts) stage of the embryo was determined by
counting the number of somites posterior to the hind limb (Hacker et al., 1995).
Using this method, 10.5 dpc corresponds to approximately 8 ts, 11.5 dpc to 18
ts, and 12.5 dpc to 30 ts. The transgenic mouse line constitutively expressing
EGFP from an autosome was a gift of A. Nagy (Hadjantonakis et al., 1998).
The TM3 cell line was originally generated by Mather (1980) and obtained
from ATCC. TM3 and COS7 cells were cultured at 37-C, 5% CO2 in
Dulbecco’s Modified Eagle Medium (DMEM, Gibco) supplemented with 10%
serum (Serum Supreme, BioWhittaker).
Antibodies
Mouse Sry cDNA (nucleotide 244–1185) was inserted in frame into the
pGEX-KG vector (Guan and Dixon, 1991) to produce a fusion protein
(GST-DSRY) consisting of glutathione-S-transferase and mouse SRY lacking
the N-terminus including the HMG domain (aa 1–81). Recombinant GST-
DSRY was purified, and a total of 2 mg was used per rabbit for
immunization. The affinity-purified antibody was used in a 1:100 dilution in
all described applications. The anti-SOX9 antibody was raised by
immunizing rabbits with a 20-mer C-terminal peptide (CPQTHSPQDWEQP-
VYTQVTR). The antibody was affinity-purified and used in a 1:500 dilution.
The rat antibody specific for platelet endothelial cell adhesion molecule-1
(PECAM-1) was obtained from BD Pharmingen, mouse anti-HA from Sigma,
and both were used in a 1:300 dilution.All secondary antibodies, goat anti-mouse Alexa Fluor 594, goat anti-rat
Alexa Fluor 594, goat anti-rabbit Alexa Fluor 488, and mouse anti-biotin Alexa
Fluor 594 were obtained from Molecular Probes and used in a 1:200 dilution.
For double immunofluorescence of SRY and SOX9, the anti-SOX9
antibody was biotinylated by dialyzing 1 mg anti-SOX9 antibody against
sodium borate buffer (0.1 M, pH 8.8), adding 250 Ag EZ link (Pierce), and
incubating for 4 h at room temperature. After addition of 20 Al of 1 M NH4Cl
and incubation for 10 min at room temperature, the biotinylated antibody was
dialyzed against PBS overnight at 4-C.
In situ hybridization
The Sry probe was synthesized from fragment p422.04 (Gubbay et al.,
1990). The probe for Sox9 was made as described before (Wright et al., 1995).
Section in situ hybridization was performed on 10 AM sections of frozen tail-
somite-staged male embryos as described previously (Tsuchida et al., 1994).
Whole-mount in situ hybridization was carried out essentially as described by
Hargrave and Koopman (1999).
Embedding and sectioning
Embryos and newborn mice were fixed in 4% paraformaldehyde (PFA) in
phosphate-buffered saline (PBS) several hours at 4-C, washed three times in
PBS at 4-C for 5 min each. For cryo-embedding, they were transferred to a
solution containing 30% sucrose in PBS and rocked overnight at 4-C. Then,
tissue samples were incubated for several hours at 4-C on a turning wheel in a
1:1 mixture of 30% sucrose in PBS and optimal cutting temperature compound
(OCT, Tissue-Tek). Finally, tissues were embedded in 100% OCT using
cryosection moulds and stored at 80-C. Embedded tissues were cut in serial
sections of 10 Am thickness using a Leica cryostat, mounted on Superfrost Plus
slides, and stored at 4-C until further use.
Immunofluorescence
COS7 cells were grown to 60–80% confluency on coverslips in 6-well
plates. Eight hours later, the cells were transfected with 4 Ag of pcHA-Sry,
pcHA-Sox9, and pcHA-Sox8 expression vector (Beverdam et al., 2003) using
Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer. After
8 h, the cells were washed with PBS and incubated with fresh DMEM (10%
serum) for another 16 h. Immunofluorescence was performed as described
previously (Beverdam et al., 2003).
Cryosections were washed three times using PBS containing 0.1% Triton
X-100 (PBTx) and blocked for 1 h in 10% heat-inactivated sheep serum (HISS)
in PBTx. Sections were then incubated overnight at 4-C with appropriate
dilution of the primary antibody in a humidified chamber. Subsequently,
samples were washed 35 min in PBTx and blocked in blocking solution for
30 min followed by a 2 h incubation at room temperature with secondary
antibody diluted in blocking solution in a humidified dark chamber. Finally,
sections were washed 35 min in PBTx and mounted in 80% glycerol in PBS.
For SRY/SOX9 double immunofluorescence, cryosections were washed
and incubated with anti-SRY and the respective secondary antibody as
described above. Subsequently, the sections were washed in PBTx, re-blocked
in blocking solution for 30 min at room temperature, and incubated with the
biotinylated anti-SOX9 antibody overnight at 4-C in a humidified chamber.
After washing with PBTx, the sections were treated with anti-Biotin Alexa
Fluor 594 for 2 h at room temperature and mounted as described above.
Stained sections were examined by confocal microscopy using a Zeiss LSM
510 META confocal microscope containing an Argon laser and a Green HeNe
laser.
Cell mixing and FACS analysis
Gonads + mesonephroi from 12.25 dpc embryos, the earliest time point
where it is possible to determine the sex under a dissecting microscope by the
presence of testis cords, were dissected in L-15 media (Sigma). Eight gonads
from GFP transgenic embryos were pooled with eight wild type gonads
as illustrated (Fig. 4A) and transferred into PBS containing 20 U/mlCollagenase
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with horizontal shaking for 20 min. Gonads were dissociated with a 21-gauge
needle, washed oncewith PBS, and pelleted at 3000 rpm (500 g) for 5min. The
pelleted chimeric cell aggregates were transferred to a six-well plate containing
DMEM (Gibco) supplemented with 10% Serum Supreme and 10 Ag/ml
Ampicillin and cultured for 36 h. Inhibitors were added to the culture media at
0.3 mM for suramin (Sigma), 1 AM BW A868C (DP inhibitor, Cayman
Chemical), and 30 AM SU5402 (FGF signaling inhibitor, Calbiochem).
Cultured cell aggregates were collected, washed with PBS, disaggregated
with a 21-gauge needle, and fixed for 20 min with 4% PFA in PBA (PBS +
0.1% BSA) at room temperature. Cell suspension was washed with PBA.
For SOX9 antibody staining, the cells were first permeabilized with 0.1%
Saponin (Sigma) in PBA for 10 min, washed with PBA, and incubated in PBA
with 10% HISS for 30 min. Rabbit anti-mouse SOX9 antibody (1:200) was
added followed by incubation at room temperature for 60 min. Pre-immune
serum was used as control. Cells were then washed with PBA and incubated
with goat anti-rabbit Alexa Fluor 594 secondary antibody (1:200 in PBA) for
60 min. After washing with PBA, cells were filtered through a 40 Am cell
strainer (BD Falcon), washed with PBS, pelleted by centrifugation for 30 min at
4-C at 3000 rpm, and resuspended in PBS.
A Becton/Dickinson FACScalibur was used to quantify unstained, GFP
fluorescent, Alexa 594 fluorescent, and dual-labeled cells. Unstained re-
aggregated wild type testes were used to set the initial cell gate, while unstained
re-aggregated GFP fluorescent testes and stained wild type testes were used to
set the fluorescent parameters.
Each experiment was performed at least three times. Two-way analysis of
variance was performed with Bonferroni post hoc test on the percent of female
cells expressingSOX9proteincompared to total femalecells for eachcombination
and each inhibitor treatment. P values were <0.001, except FGF inhibitor
treatment for XX–GFP/XY–wild type compared to untreated (P < 0.05).
Gonadal organ culture
XY and XX gonads were isolated from 11.5 dpc embryos by dissection in
L-15 media (Invitrogen) and incubated in DMEM (10% serum) with or without
500 ng/ml of prostaglandin D2 (Cayman Chemical) or 50 ng/ml FGF9 (Sigma)
for 2 h. Gonads were then cultured for 24 h on agar blocks (1.5% agar) as
described previously (Martineau et al., 1997). Treated gonads were either
subjected to whole-mount in situ hybridization or real-time RT-PCR.
RNA extraction and real-time RT-PCR
Male and female genital ridges (gonad+mesonephros) were dissected
from tail-somite-staged embryos. Two independent experiments were
performed with pooled genital ridges from four embryos per investigated
stage. Total RNA for real-time RT-PCR was isolated using the SV Total
RNA Isolation System (Promega). Samples were processed according to the
manufacturers’ protocol for FPreparation of Lysates from Small Tissue
Samples_. This process includes an on-column DNase treatment step. cDNA
was synthesized from 1 Ag total RNA (in cases where tissue samples
yielded <1 Ag, all available RNA was used, differences in starting amounts
were normalized by comparison to 18S levels) by reverse transcription
(SuperScripti III, Invitrogen) using random primers (Promega) according to
the manufacturers’ recommendations.
Target cDNA levels were analyzed by quantitative RT-PCR in quadruplicates
in 25 Al reactions containing SYBR green PCR master mix (Applied
Biosystems), 300 nM each forward and reverse primers, and 0.5 Al of the cDNA
reaction using an ABI Prism 7000 Sequence Detector System. PCR was
conducted over 40 cycles of 95-C for 15 s and 60-C for 1 min in a two-step
thermal cycle, preceded by an initial 10 min step at 95-C to activate the Amplitaq
Gold DNA polymerase. Primers were designed using Primer Express Software
(Applied Biosystems) and were as follows: Sry, forward 5V-CAGCCTG-
CAGTTGCCTCAA-3V, reverse 5V-GGTGTGCAGCTCTACTCCAGTCT-
3V; Sox9 , forward 5V-AGTACCCGCATCTGCACAAC-3V, reverse 5V-
TACTTGTAATCGGGGTGGTCT-3V; Fgf9 , forward 5V-CTATCCAGG-
GAACCAGGAAAGA-3V, reverse 5V-CTCGTTCATGCCGAGGTAGAG-
3V; Amh , forward 5V-CGAGCTCTTGCTGAAGTTCCA-3V, reverse 5V-
GAAGTCCACGGTTAGCACCAA-3V. Primer sequences for prostaglandin Dsynthetase have been described before (Bouma et al., 2004). cDNAs were
normalized against levels of 18S (forward 5V-GATCCATTGGAGGG-
CAAGTCT-3V, reverse 5V-CCAAGATCCAACTACGAGCTTTTT-3V). With
exception of Sry, all primer pairs spanned an intron. Dissociation curve
analysis was performed to verify product specificity.
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